Vildagliptin: ten years in the service for Type 2 Diabetes Mellitus patients. The journey of discovery, innovation and success in clinical practice

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Type‑2 diabetes mellitus is a multifactorial multiorgan disease. Over the last decade, the implementation of brand‑new therapeutic opportunities led to tremendous rise of research studies in the field of diabetes as well as to shift in priorities of the management of patients with type 2 diabetes from a glucocentric approach and towards holistic control of the key underlying pathophysiological processes of the disease development and progression. The use of dipeptidyl peptidase‑4 inhibitors shows good glycemic control because of physiological glucose‑dependent mechanism of action mediated with the improvement of incretin hormones effects. Moreover, dipeptidyl peptidase‑4 inhibitors have a wide range of pleiotropic effects owning to additional properties of incretins and inhibition of dipeptidyl peptidase enzymatic activity, which leads to beneficial impact on metabolic and pathogenetic processes of type 2 diabetes mellitus. Dipeptidyl peptidase‑4 inhibitors are effective drugs with good safety profile as for risks related to type‑2 diabetes and have no limitative disadvantages such as hypoglycemia and weight gain. This publication reviews vildagliptin, the first developed dipeptidyl peptidase‑4 inhibitor, with an emphasis on its use in different clinical settings of diabetes management.

About the authors

Tatyana Yulievna Demidova

Author for correspondence.
Email: deniszaykov@gmail.com
Scopus Author ID: 7003771623
ResearcherId: D-3425-2018
Russian Federation

References

  1. Del Prato S. Ten Years of Vildagliptin. Eur Endocrinol. 2017 Aug;13(2):54 55. doi: 10.17925/EE.2017.13.02.54
  2. Ahrén B, Foley JE. The Vildagliptin Experience – 25 Years Since the Initiation of the Novartis Glucagon like Peptide 1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration. Eur Endocrinol. 2017;13(2):56–61. doi: 10.17925/EE.2017.13.02.56
  3. Виллхауэр Э. Вилдаглиптин: первый инновационный ингибитор ДПП 4. / Под ред. Дедова И.И. // Сахарный диабет. —2010. — №3. — С.118 120. [Wilhauer E. Vildagliptin: the first innovative DDP-4 inhibitor. Dedov II, editor. Diabetes mellitus. 2010;(03):118 120. (In Russ).] doi: 10.14341/2072-0351-5499
  4. Strain DW, Paldánius PM. Dipeptidyl Peptidase 4 Inhibitor Development and Post authorisation Programme for Vildagliptin –Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes. Eur Endocrinol. 2017 Aug;13(2):62 67. doi: 10.17925/EE.2017.13.02.62
  5. Mathieu C, Kozlovski P, Paldánius PM. Clinical Safety and Tolerability of Vildagliptin – Insights from Randomised Trials, Observational Studies and Post marketing Surveillance. Eur Endocrinol. 2017;13(2):68–72. doi: 10.17925/EE.2017.13.02.68
  6. Nauck MA, Homberge E, Siegel EG, et al. Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C Peptide Responses. The Journal of Clinical Endocrinology & Metabolism. 1986; 63(2), 492–498. doi: 10.1210/jcem-63-2-492
  7. Nauck MA. Incretin based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011; 124(1 Suppl), S3 18. doi: 10.1016/j.amjmed.2010.11.002
  8. Ahrén B., Schweizer A., Dejager S., et al. Vildagliptin Enhances Islet Responsiveness to Both Hyper and Hypoglycemia in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2009; 94(4), 1236–1243. doi: 10.1210/jc.2008-2152
  9. Farngren J, Persson M, Schweizer A, et al. Glucagon dynamics during hypoglycaemia and food‐re‐challenge following treatment with vildagliptin in insulin‐treated patients with type 2 diabetes. Diabetes, Obesity and Metabolism. Sep 2014;16 (9): 812 818. doi: 10.1111/dom.12284
  10. Michaliszyn SF, Mari A, Lee S, et al. Beta Cell Function, Incretin Effect, and Incretin Hormones in Obese Youth Along the Span of Glucose Tolerance From Normal To Prediabetes To Type 2 Diabetes. Diabetes. 2014; 63(11), 3846–3855. doi: 10.2337/db13-1951
  11. Ahrén B, Foley JE. Improved glucose regulation in type 2 diabetic patients with DPP 4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia. 2016;(59):907–17. doi: 10.1007/s00125-016-3899-2
  12. Bae EJ. DPP 4 inhibitors in diabetic complications: role of DPP 4 beyond glucose control. Archives of Pharmacal Research. 2016; 39(8), 1114–1128. doi: 10.1007/s12272-016-0832-7
  13. Chon S, Gautier JF. An update on the effect of incretin based therapies on β cell function and mass. Diabetes and Metabolism Journal. 2016; 40(2), 99–114. doi: 10.4093/dmj.2016.40.2.99
  14. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase IV inhibitor, improves model assessed b cell function in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2005; 90(8), 4888–4894. doi: 10.1210/jc.2004-2460
  15. Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model assessed b cell function in patients with type 2 diabetes and mild hyperglycemia. Journal of Clinical Endocrinology and Metabolism. 2008; 93(1), 103–109. doi: 10.1210/jc.2007-1639
  16. Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008; 31(1), 30–35. doi: 10.2337/dc07-1616
  17. He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT. The Journal of Clinical Pharmacology. 2007; 47(5), 633–641. doi: 10.1177/0091270006299137
  18. Drucker DJ. Enhancing insulin action for the treatment of type 2 diabetes. Diabetes Care. 2003; 26(10), 2929–2940. doi: 10.2337/diacare.26.10.2929
  19. Kothari V, Galdo J, Mathews S. Hypoglycemic agents and potential anti inflammatory activity. J Inflamm. Res. 2016; 9, 27–38. doi: 10.2147/JIR.S86917
  20. Ottobelli CE, de Souza WM, da Silva TP, et al. Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects. Clinical Biochemistry. 2016; 49(7–8), 548–553. doi: 10.1016/j.clinbiochem.2016.01.003
  21. Sell H, Blüher M, Klöting N, et al. Adipose dipeptidyl peptidase 4 and obesity: Correlation with insulin resistance and depot specific release from adipose tissue in vivo and in vitro. Diabetes Care. 2013; 36(12), 4083–4090. doi: 10.2337/dc13-0496
  22. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome. Diabetes. 2011; 60(7), 1917–1925. doi: 10.2337/db10-1707
  23. Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: Recent insights from the laboratory and clinical trials of DPP4 inhibition. Circulation Research. 2015; 116(8), 1491–1504. doi: 10.1161/CIRCRESAHA.116.305665
  24. Ahmed RH, Huri HZ, Muniandy S, et al. Altered circulating concentrations of active glucagon like peptide (GLP 1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance. Clinical Biochemistry. 2017; 50, 746–749. doi: 10.1016/j.clinbiochem.2017.03.008
  25. Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP IV inhibitors. Atherosclerosis. 2013; 227(2), 349–354. doi: 10.1016/j.atherosclerosis.2012.12.018
  26. Hatwal A. Inflammation and incretins. Indian J Endocrinol Metab. 2012 Dec; 16(Suppl 2): S239–S241. doi: 10.4103/2230-8210.94259
  27. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013; 498(7452), 99–10. doi: 10.1038/nature12198
  28. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut. 2014 Sep;63(9):1513 21. doi: 10.1136/gutjnl-2014-306928
  29. Grasset E, Puel A, Charpentier J, et al. A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP 1 Resistance through an Enteric NO Dependent and Gut Brain Axis Mechanism. Cell Metabolism. 2017; 25(5), 1075–1090.e5. doi: 10.1016/j.cmet.2017.04.013
  30. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015 Dec 10;528(7581):262 266. doi: 10.1038/nature15766
  31. You Lv, Xue Zhao, Weiying Guo, et al. The Relationship between Frequently Used Glucose Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus Journal of Diabetes Research. vol. 2018, Article ID 1890978, 7 pages, 2018. doi: 10.1155/2018/1890978
  32. Zhang Q, Xiao X, Li M, et al. Vildagliptin increases butyrate producing bacteria in the gut of diabetic rats. 2017; Plos One 12(10): e0184735. doi: 10.1371/journal.pone.0184735
  33. Olivares M, Neyrinck AM, Pötgens SA, et al. The DPP 4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice. Diabetologia. 2018 May 25. doi: 10.1007/s00125-018-4647-6
  34. Finan B, Müller TD, Clemmensen C, et al. Reappraisal of GIP Pharmacology for Metabolic Diseases. Trends Mol Med. 2016 May;22(5):359 376. doi: 10.1016/j.molmed.2016.03.005
  35. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug naïve patients with Type 2 diabetes Diabet Med. 2007 Sep;24(9):955 61. doi: 10.1111/j.1464-5491.2007.02191.x
  36. B. Göke at all. Efficacy and safety of Vildagliptin monotherapy during 2 year Treatment of drug naïve patients with type 2 diabetes: Comparison with metformin. Horm Metab Res 2008; 40: 892– 895. doi: 10.1055/s-0028-1082334
  37. Evans M, Schweizer A, Foley JE. An approach to reporting pooled HbA1c reductions to maximize the accuracy of between drug comparisons: HbA1c reductions with vildagliptin monotherapy. Diabetes. 2015;(64):suppl. 1:A332. doi: 10.17925/EE.2017.13.02.56
  38. Bosi E, et al. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment naive patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 11, 2009, 506–515 doi: 10.1111/j.1463-1326.2009.01040.x
  39. Bosi E. Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin. Diabetes Care. 2007 April, Vol.30(4). doi: 10.2337/dc06-1732.
  40. Matthews DR, Dejager S, Ahren B. Vildagliptin add on to Metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2 year study. Diabet Obes Metabol 2010; 12: 780—789. doi: 10.1111/j.1463-1326.2010.01233.x.
  41. Ferrannini E, Fonseca V, Zinman B, et al. Fifty two week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;(11):157 66. doi: 10.1111/j.1463-1326.2008.00994.x
  42. Lukashevich V, Del Prato S. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes, Obesity and Metabolism 16: 403–409, 2014. doi: 10.1111/dom.12229
  43. Fonseca V, at al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007; 50:1148–1155. doi: 10.1007/s00125-007-0633-0
  44. Ved P, Shah S. Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus. Indian J Endocr Metab. 2012;16, Suppl S1:110-3. doi: 10.4103/2230-8210.94258
  45. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP 1 Receptor Agonists and DPP 4 Inhibitors: Meta Analysis and Systematic Review. Clin Ther. 2012 Jun;34(6):1247 1258, Erratum 2014 Feb;36(2):307 8. doi: 10.1016/j.clinthera.2012.04.013.
  46. Esposito K, Chiodini P, Maiorino MI, et al. A nomogram to estimate the HbA1c response to different DPP 4 inhibitors in type 2 diabetes: a systematic review and meta analysis of 98 trials with 24 163 patients. BMJ Open 2015;5:e005892. doi: 10.1136/bmjopen-2014-005892
  47. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA (1c). Diabetes Care 2003;26:881–885. doi: 10.2337/diacare.26.3.881
  48. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681–1687. doi: 10.1001/jama.295.14.1681
  49. Marso SP, McGuire DK, Zinman B. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;(377):723 732. doi: 10.1056/NEJMoa1615692
  50. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients with Type 2 Diabetes. Diabetes Care. 2012 Oct;35(10):2076 2082. doi: 10.2337/dc12-0199
  51. Chen X, Wang J, Huang X, et al. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea. Current Medical Research and Opinion. 2016;32(6):1131 1136. doi: 10.1185/03007995.2016.1162773
  52. VERIFY: A study to compare combination regimen with vildagliptin & metformin versus metformin in treatment naive patients with type 2 diabetes mellitus. https://clinicaltrials.gov/ct2/show/NCT01528254?term=vildagliptin+VERIFY&rank=1 (доступ от апреля, 2018).
  53. Ahrén B, Mathieu C, Bader G, et al. Efficacy of vildagliptin versus sulfonylureas as add on to metformin: comparison of results from randomized controlled trials and observational studies. Diabetologia. 2014;(57):1304 7. doi: 10.1007/s00125-014-3222-z
  54. Schweizer A, Dejager S. Experience with Vildagliptin in Patients >75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment. Diabetes Ther. (2013) 4:257–267. doi: 10.1007/s13300-013-0027-x
  55. McMurray JV et al., Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure A Randomized Placebo Controlled Trial, JACC Hear. Fail., 2018; 6 (1): 8–17. doi: 10.1016/j.jchf.2017.08.004
  56. Guo WQ, Li L, Su Q, et al. Effect of Dipeptidyl Peptidase 4 Inhibitors on Heart Failure: A Network Meta Analysis. Value Health. 2017 Dec; 20(10):1427 1430. doi: 10.1016/j.jval.2017.04.010
  57. McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta analysis of 17 000 patients. Diabetes Obes Metab. 2015;17:1085–92. doi: 10.1111/dom.12548
  58. Macauley M, Hollingsworth KG, Smith FE, et al. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab. 2015;(100):1578–85. doi: 10.1210/jc.2014-3794
  59. Mathieu C, Barnett AH, Brath H, et al. Effectiveness and tolerability of second line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real life worldwide observational study (EDGE). Int J Clin Pract. 2013;(67):947 56. doi: 10.1111/ijcp.12252
  60. Rosales R, Abou Jaoude E, Al Arouj M, et al. Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study. Diabetes Obes Metab. 2015 Jun;17(6):603 7. doi: 10.1111/dom.12436
  61. Bluher M et al., Efficacy and safety of vildagliptin in clinical practice results of the PROVIL study. WJD. – 2012. №3 (9). 161 169. doi: 10.4239/wjd.v3.i9.161
  62. Wlodzimierz M. Kolaczynski et al, Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records, Diabetes Ther (2016) 7:483–496. doi: 10.1007/s13300-016-0177-8
  63. Eriksson JW, Bodegard J, Nathanson D, et al. Sulphonylurea compared to DPP 4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all cause mortality. Diabetes research and clinical practice. 2016; 117: 39 47. doi: 10.1016/j.diabres.2016.04.055
  64. Williams R, de Vries F, Kothny W, et al. Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi‐database, non‐interventional post‐authorization safety study Diabetes Obes Metab. 2017; 19: 1473 1478. doi: 10.1111/dom.12951

Supplementary files

There are no supplementary files to display.

Statistics

Views

Abstract: 16

PlumX


Copyright (c) Demidova T.Y., Svet A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies